Multiple sclerosis and related disorders: Short report peripheral vascular events in a real-world cohort of multiple sclerosis patients using Fingolimod

Pelayo, Carolina; Ciampi Díaz, Ethel Leslie; Uribe San Martín, Reinaldo; Soler León, Bernardita María; Reyes, Ana; Vergara, Elizabeth; Cárcamo Rodríguez, Claudia Andrea

Multiple sclerosis and related disorders: Short report peripheral vascular events in a real-world cohort of multiple sclerosis patients using Fingolimod

Files

Multiple Sclerosis and Related Disorders.pdf(70.07 KB)

Date

2020

Authors

Pelayo, Carolina

Ciampi Díaz, Ethel Leslie

Uribe San Martín, Reinaldo

Soler León, Bernardita María

Reyes, Ana

Vergara, Elizabeth

Cárcamo Rodríguez, Claudia Andrea

Abstract

Background: Fingolimod is a high-efficacy disease-modifying therapy for multiple sclerosis (MS) and was the first oral treatment approved for the disease. Adverse events include bradyarrhythmia, hypertension, macular oedema and increased risk of infections, mainly due to its main mechanism of action, the non-selective modulation of sphingosine-1-phosphate receptor.", "Methods and Results: We report the baseline characteristics, effectiveness outcomes and adverse events of a prospective cohort of 177 patients with a median treatment duration of 24 months, in which four patients (2.3%) presented with otherwise non-provoked peripheral vascular events (PVE).", "Conclusions: Further studies are still needed to evaluate the frequency and severity of PVE in fingolimod patients.

Keywords

Multiple sclerosisDisease-modifying treatment, Fingolimod, Adverse events, Thrombosis, Peripheral vascular events

URI

https://doi.org/10.1016/j.msard.2020.102411
https://repositorio.uc.cl/handle/11534/80566

Collections

Artículos de revistas

Full item page